Edition:
United Kingdom

Athersys Inc (ATHX.OQ)

ATHX.OQ on NASDAQ Stock Exchange Capital Market

1.67USD
15 Dec 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.67
Open
$1.67
Day's High
$1.69
Day's Low
$1.66
Volume
381,290
Avg. Vol
213,712
52-wk High
$2.62
52-wk Low
$1.02

Chart for

About

Athersys, Inc. is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company's MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating... (more)

Overall

Beta: -0.38
Market Cap(Mil.): $275.67
Shares Outstanding(Mil.): 113.91
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

BRIEF-Athersys reports Q3 loss per share $0.06

* Q3 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

08 Nov 2017

BRIEF-Athersys enters agreement with Garnet to settle intellectual property disagreements

* Athersys says ‍on Oct 12, co entered into agreement with Garnet to settle intellectual property disagreements between parties​ - SEC filing Source text: (http://bit.ly/2zcHTNn) Further company coverage:

16 Oct 2017

BRIEF-Athersys and Nikon Cell Innovation to collaborate on MultiStem manufacturing in Japan

* Athersys and Nikon Cell Innovation to collaborate on multistem commercial manufacturing in Japan

11 Oct 2017

BRIEF-Athersys Q2 loss per share $0.06

* Q2 earnings per share view $-0.07 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

09 Aug 2017

BRIEF-Athersys reports alignment of key regulators for pivotal registration study in stroke

* Athersys reports alignment of key regulators for pivotal registration study in stroke

07 Aug 2017

Earnings vs. Estimates